Department of Anatomical Pathology, Canberra Hospital, Garran, ACT, Australia; Australian National University, Medical School, Garran, ACT, Australia.
Department of Endocrinology, Canberra Hospital, Garran, ACT, Australia.
Pathology. 2020 Apr;52(3):318-322. doi: 10.1016/j.pathol.2019.11.007. Epub 2020 Feb 24.
The impact of concurrent autoimmune thyroid disease on the tumour microenvironment and disease progression in papillary thyroid cancer (PTC) is not well understood. Studies evaluating the programmed cell death ligand 1 (PD-L1) tumour expression in PTC have shown variable results, and the effect of lymphocytic thyroiditis (LT) on tumour PD-L1 expression has not been adequately assessed. The main aim of this study was to determine expression of PD-L1 in PTC with and without LT. We examined 81 PTC cases; 28.5% of all reviewed PTC had presence of LT. In PTC specimens without LT, tumour PD-L1 expression was significantly lower compared to PD-L1 expression in PTC with LT, 6.9% vs 39.1%, respectively. Expression of PD-L1 did not differ with PTC stage, even when sub-categorised according to the presence and absence of LT. Utility of PD- L1 expression as a prognostic marker in thyroid cancer needs to be interpreted with caution.
自身免疫性甲状腺疾病对甲状腺乳头状癌（PTC）肿瘤微环境和疾病进展的影响尚不清楚。评估程序性死亡配体 1（PD-L1）在 PTC 中肿瘤表达的研究结果不一，淋巴细胞性甲状腺炎（LT）对肿瘤 PD-L1 表达的影响尚未得到充分评估。本研究的主要目的是确定伴有和不伴有 LT 的 PTC 中 PD-L1 的表达。我们检查了 81 例 PTC 病例；所有回顾性 PTC 的 28.5% 存在 LT。在无 LT 的 PTC 标本中，肿瘤 PD-L1 表达明显低于伴有 LT 的 PTC，分别为 6.9%和 39.1%。PD-L1 的表达与 PTC 分期无关，即使根据 LT 的存在和不存在进行亚分类也是如此。PD-L1 表达作为甲状腺癌的预后标志物的效用需要谨慎解释。
